Oncolytics Biotech Inc ONCY

Generic version of Pfizer's CDK4,6 inhibitor launched

[Noteable]

January 11, 2023 - "Sun Pharmaceutical Industries has launched the generic version of Pfizer's breast cancer medicine palbociclib (CDK4,6 inhibitor-Ibrance) in India on January 11. The entry of the generic medicine became possible after Pfizer's Indian patent on the product expired this month. The generic versions of the drug are also being readied by a handful of other Indian companies like Cipla and Dr Reddy's, and the price of the medicine is likely to come down significantly in the coming days, industry experts said."

https://www.fortuneindia.com/enterprise/sun-pharma-launches-generic-version-of-pfizers-blockbuster-cancer-drug/111110

This is the beginning of a series of patent losses that Big Pharma is set to face. 

In contrast, ONCY's pelareorep is an innovative and novel "Phase 3 ready" biologic that can potentially acheve an accelerated approval and work to off-set several Big Pharma patent losses when combined with some of those soon to be off-patent drugs such as Pfizer's CDK4,6 inhibitor Ibrance.  Furthermore, as a biologic ONCY's pelareorep is eligible for the FDA's 13 years of market exclusivity from the day of the marketing approval is granted.

[Noteable]

With pharma recording appoximately $900 billion in 2021 revenue, about $230 billion of that $900 billion will lose patent protection between 2025 and 2030, according to a Goldman Sachs analysis cited by The Wall Street Journal. Companies will have to find a way to bridge that growth gap. Merck may be one biopharma poised for a megadeal. The drugmaker had been in talks to acquire Seagen

[Noteable]

More M&A Bibhash Mukhopadhyay, managing partner of venture capital fund Sound Bioventures, anticipated “an uptick in M&A and partnering in general, at all levels of capital spend (few millions to multi-billions), all across the biotech ‘food chain’.” He noted that the decline in the number and value of deals in 2022 had created “pent-up demand in 2023.” He thought there would be a

[TitanBrawler]

I wouldn't be surprised if this company gets a 100 billion dollar buyout.  This is a Golden opportunity to buy  as much as possible.  Back up the truck... Mortgage the house.. Get the golden goose that will make you a millionaire over night. Big grin.

[Azzak34]

Yes Titanbrawler, glad to have you back on the team. I'll copy this around the other boards and give you full credit. Good man. 

[TitanBrawler]

Thx. Much appreciated.  Nothing would make me happier!!! (Bigger grin)

[westcoast1000]

Noteable,  Along the lines of your post on Ibrance expiry, is it the case that if pela were included in a combo treatment with Ibrance and other agents, and that combo were approved and licensed, then the combo would recieve the 13 year market exclusivity?

[Noteable]

westcoast - that is what would effectively happen. By having this specific combination approved in a specific indication, the exclusivity of the off-patent small molecule (i.e. Ibrance) would be extended by virtue of the novel biologic agent (i.e. pelareorep).

[westcoast1000]

Thanks Noteable. That is very encouraging. So our message to big pharma is : show us the money so you can make money and save lives, as well as meet your strategic plans and achieve your bonuses. 

[westcoast1000]

Finishing my note to Noteable: ....and also effectively extend your patents by doing combos with pela!